Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database
- 141 Downloads
Epidemiological data are pivotal for the estimation of disease burden in populations.
Of the study was to estimate the incidence and prevalence of acromegaly in Italy along with the impact of comorbidities and hospitalization rates as compared to the general population.
Retrospective epidemiological study (from 2000 to 2014) and case control-study. Data were extracted from the Health Search Database (HSD). HSD contains patient records from about 1000 general practitioners (GPs) throughout Italy, covering a population of more than 1 million patients. It includes information about patient demographics and medical data including clinical diagnoses and diagnostic tests.
At the end of the study period, 74 acromegaly patients (out of 1,066,871 people) were identified, resulting in a prevalence of 6.9 per 100,000 inhabitants [95% CI 5.4–8.5]. Prevalence was higher in females than men (p = 0.004), and showed a statistically significant trend of increase over time (p < 0.0001). Overall, incidence during the study period was 0.31 per 100,000 person-years. Hypertension and type II diabetes mellitus were the comorbidities more frequently associated with acromegaly (31.3 and 14.6%, respectively) and patients were more likely to undergo a high frequency of yearly hospitalization (≥3 accesses/year, p < 0.001) compared to sex-age matched controls.
This epidemiological study on acromegaly carried out using a large GP-based database, documented a disease prevalence of about 7 cases per 100,000 inhabitants. As expected, acromegaly was associated with a number of comorbidities (mainly hypertension and type II diabetes mellitus) and a high rate of patients’ hospitalization.
KeywordsAcromegaly Epidemiology Prevalence Incidence Comorbidities
This research received the unconditional support of Pfizer srl.
Compliance with ethical standards
Conflict of interest
F.G. received fees for lectures and/or participation to advisory boards for Novartis, AMCo, and IONIS Pharmaceuticals. D.F. received grants and fees for lectures and participation to advisory boards for Novartis, Ipsen, and Pfizer. The remaining authors have declare that they have no conflict of interest.
- 7.T.T. Agustsson, T. Baldvinsdottir, J.G. Jonasson, E. Olafsdottir, V. Steinthorsdottir, G. Sigurdsson, A.V. Thorsson, P.V. Carroll, M. Korbonits, R. Benediktsson, The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur. J. Endocrinol. 173(5), 655–664 (2015). https://doi.org/10.1530/EJE-15-0189 CrossRefPubMedGoogle Scholar
- 11.J. Dal, U. Feldt-Rasmussen, M. Andersen, L.O. Kristensen, P. Laurberg, L. Pedersen, O.M. Dekkers, H.T. Sorensen, J.O. Jorgensen, Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study. Eur. J. Endocrinol. 175(3), 181–190 (2016). https://doi.org/10.1530/EJE-16-0117 CrossRefPubMedGoogle Scholar
- 12.A. Mestron, S.M. Webb, R. Astorga, P. Benito, M. Catala, S. Gaztambide, J.M. Gomez, I. Halperin, T. Lucas-Morante, B. Moreno, G. Obiols, P. de Pablos, C. Paramo, A. Pico, E. Torres, C. Varela, J.A. Vazquez, J. Zamora, M. Albareda, M. Gilabert, Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur. J. Endocrinol. 151(4), 439–446 (2004)CrossRefPubMedGoogle Scholar
- 20.R. Kauppinen-Makelin, T. Sane, A. Reunanen, M.J. Valimaki, L. Niskanen, H. Markkanen, E. Loyttyniemi, T. Ebeling, P. Jaatinen, H. Laine, P. Nuutila, P. Salmela, J. Salmi, U.H. Stenman, J. Viikari, E. Voutilainen, A nationwide survey of mortality in acromegaly. J. Clin. Endocrinol. Metab. 90(7), 4081–4086 (2005). https://doi.org/10.1210/jc.2004-1381 CrossRefPubMedGoogle Scholar
- 22.M. Arosio, G. Reimondo, E. Malchiodi, P. Berchialla, A. Borraccino, L. De Marinis, R. Pivonello, S. Grottoli, M. Losa, S. Cannavo, F. Minuto, M. Montini, M. Bondanelli, E. De Menis, C. Martini, G. Angeletti, A. Velardo, A. Peri, M. Faustini-Fustini, P. Tita, F. Pigliaru, G. Borretta, C. Scaroni, N. Bazzoni, A. Bianchi, M. Appetecchia, F. Cavagnini, G. Lombardi, E. Ghigo, P. Beck-Peccoz, A. Colao, M. Terzolo; Italian Study Group of, A., Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur. J. Endocrinol. 167(2), 189–198 (2012). https://doi.org/10.1530/EJE-12-0084 PubMedCrossRefGoogle Scholar
- 23.L. Maione, T. Brue, A. Beckers, B. Delemer, P. Petrossians, F. Borson-Chazot, O. Chabre, P. Francois, J. Bertherat, C. Cortet-Rudelli, P. Chanson; French Acromegaly Registry, G., Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. Eur. J. Endocrinol. 176(5), 645–655 (2017). https://doi.org/10.1530/EJE-16-1064 CrossRefPubMedGoogle Scholar
- 24.A. Giustina, P. Chanson, D. Kleinberg, M.D. Bronstein, D.R. Clemmons, A. Klibanski, A.J. van der Lely, C.J. Strasburger, S.W. Lamberts, K.K. Ho, F.F. Casanueva, S. Melmed; Acromegaly Consensus, G., Expert consensus document: a consensus on the medical treatment of acromegaly. Nature reviews. Endocrinology 10(4), 243–248 (2014). https://doi.org/10.1038/nrendo.2014.21 PubMedCrossRefGoogle Scholar
- 25.E. Lesen, D. Granfeldt, A. Houchard, J. Dinet, A. Berthon, D.S. Olsson, I. Bjorholt, G. Johannsson, Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. Eur. J. Endocrinol. 176(2), 203–212 (2017). https://doi.org/10.1530/EJE-16-0623 CrossRefPubMedGoogle Scholar
- 28.G. Trifiro, P. Morabito, L. Cavagna, C. Ferrajolo, S. Pecchioli, M. Simonetti, E. Bianchini, G. Medea, C. Cricelli, A.P. Caputi, G. Mazzaglia, Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann. Rheum. Dis. 72(5), 694–700 (2013). https://doi.org/10.1136/annrheumdis-2011-201254 CrossRefPubMedGoogle Scholar
- 29.G. Mazzaglia, E. Ambrosioni, M. Alacqua, A. Filippi, E. Sessa, V. Immordino, C. Borghi, O. Brignoli, A.P. Caputi, C. Cricelli, L.G. Mantovani, Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 120(16), 1598–1605 (2009). https://doi.org/10.1161/CIRCULATIONAHA.108.830299 CrossRefPubMedGoogle Scholar
- 32.L.A. Naves, L.B. Porto, J.W. Rosa, L.A. Casulari, J.W. Rosa, Geographical information system (GIS) as a new tool to evaluate epidemiology based on spatial analysis and clinical outcomes in acromegaly. Pituitary 18(1), 8–15 (2015). https://doi.org/10.1007/s11102-013-0548-3 CrossRefPubMedGoogle Scholar
- 35.J. Dal, N. Skou, E.H. Nielsen, J.O. Jorgensen, L. Pedersen, Acromegaly according to the Danish National Registry of Patients: how valid are ICD diagnoses and how do patterns of registration affect the accuracy of registry data? Clin. Epidemiol. 6, 295–299 (2014). https://doi.org/10.2147/CLEP.S63758 CrossRefPubMedPubMedCentralGoogle Scholar
- 36.S. Fieffe, I. Morange, P. Petrossians, P. Chanson, V. Rohmer, C. Cortet, F. Borson-Chazot, T. Brue, B. Delemer; French Acromegaly, R., Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur. J. Endocrinol. 164(6), 877–884 (2011). https://doi.org/10.1530/EJE-10-1050 CrossRefPubMedGoogle Scholar
- 37.S. Petersenn, M. Buchfelder, M. Reincke, C.M. Strasburger, H. Franz, R. Lohmann, H.J. Quabbe, U. Plockinger, Participants of the German Acromegaly, R.: Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register. Eur. J. Endocrinol. 159(5), 525–532 (2008). https://doi.org/10.1530/EJE-08-0498 CrossRefPubMedGoogle Scholar
- 38.L.A. Portocarrero-Ortiz, A. Vergara-Lopez, M. Vidrio-Velazquez, A.M. Uribe-Diaz, A. Garcia-Dominguez, A.A. Reza-Albarran, D. Cuevas-Ramos, V. Melgar, J. Talavera, A.J. Rivera-Hernandez, C.V. Valencia-Mendez, M. Mercado, Mexican Acromegaly Registry, G.: The Mexican Acromegaly Registry: Clinical and Biochemical Characteristics at Diagnosis and Therapeutic Outcomes. J. Clin. Endocrinol. Metab. 101(11), 3997–4004 (2016). https://doi.org/10.1210/jc.2016-1937 CrossRefPubMedGoogle Scholar
- 39.P. Petrossians, A.F. Daly, E. Natchev, L. Maione, K. Blijdorp, M. Sahnoun-Fathallah, R. Auriemma, A.M. Diallo, A.L. Hulting, D. Ferone, V. Hana Jr., S. Filipponi, C. Sievers, C. Nogueira, C. Fajardo-Montanana, D. Carvalho, V. Hana, G.K. Stalla, M.L. Jaffrain-Rea, B. Delemer, A. Colao, T. Brue, S. Neggers, S. Zacharieva, P. Chanson, A. Beckers, Acromegaly at diagnosis in 3173 patients from the Liege Acromegaly Survey (LAS) Database. Endocr.-Relat. Cancer 24(10), 505–518 (2017). https://doi.org/10.1530/ERC-17-0253 CrossRefPubMedPubMedCentralGoogle Scholar
- 42.R. Gini, M.J. Schuemie, G. Mazzaglia, F. Lapi, P. Francesconi, A. Pasqua, E. Bianchini, C. Montalbano, G. Roberto, V. Barletta, I. Cricelli, C. Cricelli, G. Dal Co, M. Bellentani, M. Sturkenboom, N. Klazinga, Automatic identification of type 2 diabetes, hypertension, ischaemic heart disease, heart failure and their levels of severity from Italian General Practitioners’ electronic medical records: a validation study. BMJ Open 6(12), e012413 (2016). https://doi.org/10.1136/bmjopen-2016-012413 CrossRefPubMedPubMedCentralGoogle Scholar
- 43.T.J. Reid, K.D. Post, J.N. Bruce, M. Nabi Kanibir, C.M. Reyes-Vidal, P.U. Freda, Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin. Endocrinol. 72(2), 203–208 (2010). https://doi.org/10.1111/j.1365-2265.2009.03626.x CrossRefGoogle Scholar